Sign In

Jonathan Pachter

Chief Scientific Officer at Verastem

Jonathan Pachter is the Chief Scientific Officer at Verastem, a biotech company that develops drugs for cancer treatment.12 He has over 30 years of experience in leading discovery and translational research for anti-cancer therapeutics, including small molecules and monoclonal antibodies.2

Dr. Pachter joined Verastem in July 2011 as Vice President and Head of Research, and was promoted to Chief Scientific Officer in April 2016.1 Prior to Verastem, he held leadership positions at other pharmaceutical companies:

  • Senior Director of Cancer Biology at OSI Pharmaceuticals (2005-2011)
  • Senior Research Fellow at Schering-Plough Research Institute (1989-2005)

His educational background includes:

  • Postdoctoral work in Pharmacology at Yale University School of Medicine (1985-1989)
  • Ph.D. in Neuroscience from Baylor College of Medicine (1981-1985)
  • M.S. in Pharmacology from Baylor College of Medicine (1979-1981)
  • B.S. in Biology from the University of Rochester (1975-1979)

Dr. Pachter has made significant contributions to cancer drug development, including advancing five small molecules into development at OSI Pharmaceuticals and progressing three agents into development at Schering-Plough.2 He is an author of over 50 peer-reviewed publications and an inventor on numerous patents.2

Highlights

Jan 29 · verastem.com
Leadership | Verastem-2024
Leadership | Verastem-2024
Jan 9 · verastem.com
Resources | Verastem-2024

Related Questions

What are Jonathan Pachter's key achievements at Verastem?
How did Jonathan Pachter transition from academia to industry?
What is the significance of RAF/MEK clamp avutometinib in cancer treatment?
Can you provide more details about Jonathan Pachter's work at OSI Pharmaceuticals?
What are the latest developments in RAS pathway-driven cancer therapies?
Jonathan Pachter
Jonathan Pachter, photo 1
Jonathan Pachter, photo 2
Add to my network

Location

Greater Boston